FDA: "HIGHLIGHTS OF PRESCRIBING INFORMATION INVEGA TRINZATM", 1 May 2015 (2015-05-01) - 21 January 2021 (2021-01-21), XP093007896, Retrieved from the Internet <URL:https://www.accessdata.fda.gov/drugsatfda_docs/label/2015> [retrieved on 20210121] (B1)

JORIS BERWAERTS ET AL: "Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia : A Randomized Clinical Trial", JAMA PSYCHIATRY, vol. 72, no. 8, 25 March 2015 (2015-03-25), pages 830, XP055525842, ISSN: 2168-622X, DOI: 10.1001/jamapsychiatry.2015.0241 (B1)

PIERRE CHUE ET AL: "A review of paliperidone palmitate", EXPERT REVIEW OF NEUROTHERAPEUTICS, vol. 12, no. 12, 9 December 2012 (2012-12-09), GB, pages 1383 - 1397, XP055525726, ISSN: 1473-7175, DOI: 10.1586/ern.12.137 (B1)

US-A1- 2011 105 536 (B1)

SRIHARI GOPAL ET AL: "Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophrenia", CURRENT MEDICAL RESEARCH AND OPINION, vol. 31, no. 11, 2 October 2015 (2015-10-02), GB, pages 2043 - 2054, XP055627208, ISSN: 0300-7995, [retrieved on 20210121], DOI: 10.1185/03007995.2015.1085849 (B1)

US-A1- 2009 163 519 (B1)

RICHARD H OSBORNE ET AL: "Health-related quality of life advantage of long-acting injectable antipsychotic treatment for schizophrenia: a time trade-off study", HEALTH AND QUALITY OF LIFE OUTCOMES, BIOMED CENTRAL, LONDON, GB, vol. 10, no. 1, 2 April 2012 (2012-04-02), pages 35, XP021095723, ISSN: 1477-7525, DOI: 10.1186/1477-7525-10-35 (B1)